Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

2.925 -0.095 (-3.15%)

Streaming Delayed Price Updated: 3:04 PM EDT, Jul 8, 2026 Add to My Watchlist

Price and Volume

Volume	1,318,696
Open	2.920
Bid (Size)	2.920 (1,500)
Ask (Size)	2.930 (1,100)
Prev. Close	3.020
Today's Range	2.835 - 3.075
52wk Range	0.9100 - 3.210
Shares Outstanding	98,384,456
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

July 06, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

July 01, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+196.5%	+196.5%
1 Month	+53.1%	+53.1%
3 Month	+154.3%	+154.3%
6 Month	+189.6%	+189.6%
1 Year	+175.9%	+175.9%

More News

Fate Therapeutics Appoints Laura Hamill to Board of Directors

June 15, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

June 12, 2026

From Equity Insider

Via GlobeNewswire

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

June 08, 2026

From Biotech Insider

Via GlobeNewswire

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

June 04, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

June 01, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 21, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

Via FinancialNewsMedia

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

May 14, 2026

Via FinancialNewsMedia

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 11, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 05, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 04, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

April 30, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR

April 16, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

April 09, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

From USA News Group

Via GlobeNewswire

Friday's after hours session: top gainers and losers ↗

March 13, 2026

Via Chartmill

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

March 03, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

February 26, 2026

From Fate Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fate Therapeutics, Inc. - Common Stock trade on?

Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?

The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market

What is the current price of Fate Therapeutics, Inc. - Common Stock?

The current price of Fate Therapeutics, Inc. - Common Stock is 2.925

When was Fate Therapeutics, Inc. - Common Stock last traded?

The last trade of Fate Therapeutics, Inc. - Common Stock was at 07/08/26 03:04 PM ET

What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?

The market capitalization of Fate Therapeutics, Inc. - Common Stock is 287.77M

How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?

Fate Therapeutics, Inc. - Common Stock has 288M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.